Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-004961-14-SE
EUCTR2013-004961-14-SE
Active, not recruiting
Phase 1

Pilot study to investigate the mode of action (MoA) of Uro-Vaxom® on a molecular level in pre-menopausal women suffering from recurrent urinary tract infections (rUTI) - OM-89 Modes of action study in women with recurrent UTI

Kliniken Kärnan Urology Centre0 sites10 target enrollmentApril 29, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsUro-Vaxom

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Kliniken Kärnan Urology Centre
Enrollment
10
Status
Active, not recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 29, 2014
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
Kliniken Kärnan Urology Centre

Eligibility Criteria

Inclusion Criteria

  • •Otherwise healthy pre\-menopausal females who are naïve to OM\-89 prophylaxis (\>18 years old) suffering from recurrent non\-febrile lower UTI (\=3 UTIs in previous year. UTI episodes should be documented by repeated cultures and at least 2 clinical symptoms and there should be a minimum interval of 2 weeks between each infection episode).
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 10
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- Diabetes mellitus type 1
  • •\- Poorly controlled diabetes mellitus type 2
  • •\- Treatment of malignant diseases in the past two years
  • •\- Corticosteroid treatment
  • •\- Auto\-immune disorders
  • •\- Immune deficiency or immune compromised conditions
  • •\- Multiple sclerosis
  • •\- Women: pregnant or intending to be pregnant and not using acceptable contraceptives, menopausal status
  • •\- Previous OM\-89 treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Pilot study for the evaluation, development and implementation of a breath test to diagnose oral candidiasisB37.0Candidal stomatitis
DRKS00009391Charité Campus Charité Mitte20
Completed
Not Applicable
Pilot study for the evaluation, development and implementation of a breath test for the early detection of squamous cell carcinomas in the head and neck area (SCCHN).C01C02C04C05C06C09C10Malignant neoplasm of base of tongueMalignant neoplasm of other and unspecified parts of tongueMalignant neoplasm of floor of mouthMalignant neoplasm of palateMalignant neoplasm of other and unspecified parts of mouthMalignant neoplasm of tonsilMalignant neoplasm of oropharynx
DRKS00009539Charité Campus Charité Mitte11
Completed
Phase 2
Study of a combination of fenugreek/phaseolamin as a new weight loss agentObesityDiet and Nutrition - Obesity
ACTRN12607000130460Southern European Health Marketing Ltd39
Active, not recruiting
Phase 1
A Prospective Pilot Study to Investigate the Effectiveness of Quinagolide in the Improvement of Psychological Symptoms Associated with Hyperprolactinaemia. - A)Dopamine agonists and psychological disorders of hyperprolactinaemiaHyperprolactinaemiaMedDRA version: 12.1Level: LLTClassification code 10020737Term: Hyperprolactinaemia
EUCTR2010-021403-24-GBorth Lincolnshire and Goole NHS Foundation Trust40
Completed
Not Applicable
Effect of Ayurveda and yoga-based health practices on the general wellness of the health seekers
CTRI/2021/02/031235BOSCH INDIA FOUNDATIO278